Empagliflozin
Jump to navigation
Jump to search
| Drug monograph · NCLEX study reference | |
| Trade names | Jardiance |
|---|---|
| Therapeutic class | Antidiabetic, heart failure and renal protective agent |
| Pharmacologic class | SGLT2 inhibitor |
| Onset / peak / duration | Peak 1 to 2 hours; once-daily effect. |
| Half-life / level | Half-life about 12 hours; no routine level. |
| Routes | PO (oral) |
| High-alert (ISMP) | No |
| Black box warning | None |
| Antidote / reversal | None; supportive. |
| Pregnancy / lactation | Not recommended in second and third trimesters. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Empagliflozin (brand name Jardiance) — Antidiabetic, heart failure and renal protective agent; SGLT2 inhibitor.
Identification
- Therapeutic class: Antidiabetic, heart failure and renal protective agent.
- Pharmacologic class: SGLT2 inhibitor.
Pharmacology
- Mechanism of action: Blocks glucose reabsorption in the kidney, increasing urinary glucose excretion; also reduces heart failure and kidney disease progression.
- Onset / peak / duration: Peak 1 to 2 hours; once-daily effect.
- Half-life / therapeutic level: Half-life about 12 hours; no routine level.
Clinical use
- Indications: Type 2 diabetes, heart failure, chronic kidney disease, cardiovascular risk reduction.
- Usual dose, route, frequency: 10 to 25 mg PO once daily in the morning.
- Maximum dose / adjustments: Max 25 mg/day; glucose-lowering effect lessens at low eGFR though cardiorenal benefit persists.
Safety
- Contraindications: Type 1 diabetes (ketoacidosis risk), dialysis.
- Black box warning: None.
- Interactions: Diuretics (volume depletion), insulin and secretagogues (hypoglycemia).
- Pregnancy / lactation: Not recommended in second and third trimesters.
- High-alert: No.
Adverse effects
- Common side effects: Genital yeast infections, urinary frequency, thirst, mild volume depletion.
- Serious effects to report: Euglycemic diabetic ketoacidosis, serious urinary or genital infection (Fournier gangrene), severe dehydration.
- Antidote / reversal: None; supportive.
Nursing process
- Assessment before administration: Renal function, volume status, blood pressure, genitourinary infection history.
- Interventions during therapy: Encourage genital hygiene and hydration; hold during acute illness or before major surgery.
- Monitor: Renal function, glucose, volume status, A1c.
- Evaluation / expected outcome: Glycemic control plus cardiorenal protection.
Patient teaching
- Patient teaching: Maintain hydration and hygiene; sick-day guidance to pause the drug.
- Notify provider if: Nausea or trouble breathing with normal glucose, genital pain or swelling, signs of infection.
- Administration tips: Morning dosing with or without food.